Search

everythinglearnresearchcommunity

for

Search:↓

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.

The user is considering using Ruderma to maintain hair and is concerned about potential hair loss acceleration due to starting TRT. They are also inquiring about the use of minoxidil, RU58841, and a derma roller for hair maintenance.

Post Finasteride Syndrome (PFS) is debated, with some users reporting severe side effects from finasteride, while others believe these effects are rare or psychosomatic. Treatments discussed include finasteride, minoxidil, and RU58841.

The user is experiencing reduced hair shedding and increased hair density after using finasteride, minoxidil, derma rolling, granactive retinoid, and Nizoral, while also taking testosterone and aromatase inhibitors. They question if they are a hyper responder to the treatments, despite mixed feedback from others about visible progress.

Koshine 826 (Pyrilutamide) has mixed reviews, with some users experiencing side effects like insomnia and others seeing minimal results. Concerns about the company's transparency and lack of progress photos are noted.

Making a hair solution using RU58841 from raw powder. Users humorously compare the process to a science experiment.

Pyrilutamide (KX826) sourcing and pricing, with users discussing the legitimacy and cost of grey market versus official sources. The conversation highlights the high cost of official products and the effectiveness of grey market versions.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

A user stopped using RU58841 after discovering their girlfriend's unplanned pregnancy, expressing concern about potential harm to the baby. Others advised consulting a doctor, waiting for health scans, and considering switching to oral finasteride or natural supplements like saw palmetto.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

User experienced hair thickening with pyri but also side effects like reduced sex drive. Stopping pyri and returning to CB restored sex drive, suggesting pyri may go systemic or be incorrectly formulated.

The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

A 24-year-old with hair thinning is using a regimen including dutasteride, RU58841, HGH, GHK-cu, and other compounds to protect and regrow hair. They are also incorporating a mild cutting cycle with testosterone propionate, anavar, and tirzepatide.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.

The conversation discusses hair loss treatments, specifically the use of RU58841 by individuals who did not respond to dutasteride. Users share experiences with maintaining hair using RU58841 and mention trying pyrilutamide and the upcoming availability of pp405.

The conversation discusses hair shedding after starting a treatment regimen including topical dutasteride, RU58841, minoxidil, and keto shampoo. Shedding is considered normal, and users suggest adjustments like increasing dutasteride dosage or using oral medications for better results.

PP405 might take 3-4 years to be available, but some claim Everychem offers a similar product, though its effectiveness is debated. Users discuss the risks of using untested grey market products and the potential for adverse effects.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

The conversation discusses using RU58841 as a topical treatment for hair loss, with some users reporting no systemic issues. The original poster is considering RU58841 due to limited progress with dutasteride and oral minoxidil.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

A 26-year-old individual treating hair loss since 19, using a regimen of Finasteride, Cyproterone, Oral Minoxidil, Microneedling, Dutasteride, and newly added RU58841. They're seeking advice from other RU58841 users about their experiences.

A user shared their positive experience with a non-surgical hair replacement system, detailing the purchase and maintenance process, including using Walker Lace Front Support Tape and various adhesives. They found the system secure and undetectable, allowing them to engage in active pursuits without issues.

The conversation discusses the use of pyrilutamide for hair loss, specifically its impact on shedding. The user is inquiring if others have experienced increased or decreased shedding after starting pyrilutamide.

Koshine 826 (Pyrilutamide) is being used by several users to address hair loss, with mixed results on shedding and side effects. Some users report reduced shedding and no side effects, while others experience increased shedding and potential issues with libido and erectile dysfunction.

An update on the use of Pyrilutamide, a new drug for hair loss, which has resulted in no shedding or testicle ache; other users have questioned the science behind this and shared their own experiences with Finasteride, Minoxidil, and microneedling.

RU58841 is effective when used once daily. Using it twice daily may require reducing the dosage, potentially decreasing its effectiveness.

Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.